{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-021152","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.868972+00:00","generated_at":"2026-06-05T12:02:15.957106+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Treace Medical reports Q4 revenue $62.2M (+25% YoY), FY2023 $187.1M (+32%); guides FY2024 $220-225M","bullets":["Q4 2023 revenue $62.2M, up 25% YoY; full-year revenue $187.1M, up 32%, above guidance of $182-186M.","Q4 net loss ($6.3M) ($0.10/share); full-year net loss ($49.5M) ($0.81/share); adjusted net loss same.","Active surgeons reached 2,855 (+20% YoY); direct sales reps 227 (+35% YoY).","FY2024 revenue guidance $220-225M (18-20% growth); expects ~50% improvement in Adjusted EBITDA.","Launched SpeedPlate, Micro-Lapiplasty, Hammertoe Fixation; patent portfolio 57 granted US patents."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-021152","json":"https://secwatch.observer/filing/0000950170-24-021152.json","markdown":"https://secwatch.observer/filing/0000950170-24-021152.md","text":"https://secwatch.observer/filing/0000950170-24-021152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000095017024021152/0000950170-24-021152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000095017024021152/tmci-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:02:15.957106+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ebb5457527a2e5d0151a91753332d339c38d7f97","claim":"TREACE MEDICAL CONCEPTS, INC. updated its the quarter and year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On February 27, 2024, Treace Medical Concepts, Inc. (the “Company”) issued a press release regarding its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630627/000095017024021152/0000950170-24-021152-index.htm","confidence":0.65,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}